Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Vyfhuis MAL, Burrows WM, Bhooshan N, Suntharalingam M, Donahue JM, Feliciano J, Badiyan S, Nichols EM, Edelman MJ, Carr SR, Friedberg J, Henry G, Stewart S, Sachdeva A, Pickering EM, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: bhooshan n. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):445-452. doi: 10.1016/j.ijrobp.2018.02.003. Epub 2018 Feb 13. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559292
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Scilla KA, et al. Among authors: bhooshan n. Oncologist. 2017 Jun;22(6):737-742. doi: 10.1634/theoncologist.2016-0443. Epub 2017 May 22. Oncologist. 2017. PMID: 28533476 Free PMC article.
Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
Vyfhuis MAL, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, Nichols EM, Feliciano J, Bentzen SM, Badiyan S, Carr SR, Friedberg J, Simone CB 2nd, Edelman MJ, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: bhooshan n. Adv Radiat Oncol. 2017 Jul 31;2(3):259-269. doi: 10.1016/j.adro.2017.07.009. eCollection 2017 Jul-Sep. Adv Radiat Oncol. 2017. PMID: 29114590 Free PMC article.
Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: bhooshan n. Lung Cancer. 2017 Dec;114:44-49. doi: 10.1016/j.lungcan.2017.10.016. Epub 2017 Nov 2. Lung Cancer. 2017. PMID: 29173764
Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
Rice SR, Vyfhuis MAL, Scilla KA, Burrows WM, Bhooshan N, Suntharalingam M, Edelman MJ, Feliciano J, Badiyan SN, Simone CB 2nd, Bentzen SM, Feigenberg SJ, Mohindra P. Rice SR, et al. Among authors: bhooshan n. Clin Lung Cancer. 2020 May;21(3):e130-e141. doi: 10.1016/j.cllc.2019.08.009. Epub 2019 Sep 18. Clin Lung Cancer. 2020. PMID: 31708388
Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: bhooshan n. Lung Cancer. 2018 Feb;116:105. doi: 10.1016/j.lungcan.2017.12.011. Epub 2017 Dec 27. Lung Cancer. 2018. PMID: 29289353 No abstract available.
Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.
Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL. Lin SH, et al. Among authors: bhooshan n. Radiother Oncol. 2017 Jun;123(3):376-381. doi: 10.1016/j.radonc.2017.04.013. Epub 2017 Apr 25. Radiother Oncol. 2017. PMID: 28455153
A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.
Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, James SE, Evans JD, Spears GM, Komaki R, Haddock MG, Mehta MP, Hallemeier CL, Merrell KW. Lester SC, et al. Among authors: bhooshan n. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):820-828. doi: 10.1016/j.ijrobp.2017.02.021. Epub 2017 Feb 20. Int J Radiat Oncol Biol Phys. 2017. PMID: 28476435
22 results